---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092691"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2026-08-07T20:06:19+00:00"
generated_at: "2026-08-07T20:08:34.236364+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# CytoSorbents Q2 2026 presentation omits financials; targets H2 2026 break-even

## Summary
- Targets operating cash-flow break-even in H2 2026 via strategic workforce and cost reduction plan.
- Restructuring direct sales team and strategy in Germany; cites war in Iran as a risk factor.
- Seeks FDA and Health Canada regulatory approval; must comply with existing debt covenants.
- Q2 2026 earnings presentation dated Aug 6, 2026; no specific revenue or EPS figures in furnished exhibit.

## SEC filing metadata
- accession: 0001104659-26-092691
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2026-08-07T20:06:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/0001104659-26-092691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/tm2622604d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092691
- JSON: https://secwatch.observer/filing/0001104659-26-092691.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.